Hepatocellular Carcinoma: An Update on Screening & Diagnosis and the Implications of Disease Progression

Supported by educational grants from Bayer & Exelixis, Inc. 

TITLE - Hepatocellular Carcinoma: An Update on Screening & Diagnosis and the Implications of Disease Progression

TARGET AUDIENCE - Target audiences for this program are Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Oncology Pharmacists, Oncology Nurses, and Nurses

LEARNING OBJECTIVES - After completing the program, Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Oncology Pharmacists, Oncology Nurses, and Nurses

  1. Describe the hepatic anatomy and the pathophysiology of hepatocellular carcinoma (HCC)
  2. Recognize the importance of screening, surveillance and diagnosis of HCC for optimal treatment 
  3. Describe current guidelines for screening for HCC
  4. Discuss classification and staging systems used for HCC and their role in guiding treatment selection
  5. List common complications and comorbid conditions associated with HCC
  6. Identify an appropriate treatment option for patients with HCC based on clinical characteristics and treatment history

Faculty Disclosures:

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/ services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by the Specialty Pharma Education Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty Disclosure: Tara E. Koehler, PharmD, BCACP, has no relevant conflicts of interest to disclose. She does not intend to discuss non-FDA approved drugs or investigational use of any product/device. 

Pharmacist continuing education credit

Specialty Pharma Education Center (SPEC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.0 hour (0.10CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test (score of 70% or higher). Participants will have 3 opportunities to pass the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
ACPE #0535-0000-20-002-H01-P

Knowledge Based Activity

Course release date 2/26/2020

Course expires 2/26/2023

Nursing continuing education credit

Educational Review Systems is an approved provider of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider # 5-115. This program is approved for 1.0 hour of continuing nursing education. 

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia. 

Course release date: 3/13/2020

Course expires: 3/13/2022

Credit Information

Activity Number Credit Amount Accreditation Period
0535-0000-20-002-H01-P 0.1 CEUs February 26, 2020 - February 26, 2023
0535-0000-20-002-H01-N 1 hour of CNE March 13, 2020 - March 13, 2022